Chris M Kozma1, Peter J Weiden2. 1. Independent Research Consultant and Adjunct Professor, College of Pharmacy, University of South Carolina, Columbia, SC. 2. Professor of Psychiatry and Director of Psychotic Disorders Program, Department of Psychiatry, University of Illinois at Chicago, IL.
Abstract
OBJECTIVE: To investigate the relationship between partial compliance with antipsychotic medication and mental health hospitalization in managed care patients with schizophrenia. STUDY DESIGN: We performed a retrospective evaluation of 1499 outpatients with ≥1 antipsychotic claims and a diagnosis of schizophrenia in a managed care database (PHARMetrics). METHODS: Patients were followed for 12 months after their initial oral antipsychotic prescribing event. Compliance was estimated by gaps in medication therapy, medication consistency and persistence, and medication possession ratio. Categorical and logistic regression analyses modeled effects of compliance, age, and gender on hospitalization risk. RESULTS: The managed care cohort had an overall hospitalization risk of 5.9% during follow-up. Increased hospitalization risk was associated with lower partial compliance, as measured by 3 of the 4 definitions. Patients with a maximum gap of >30 days were 4.7 times more likely to be hospitalized than those with a maximum gap of 0 to 10 days (P <.001). Low medication consistency of <70% and a medication possession ratio of <70% were significantly associated with increased risk of hospitalization (P <.001). Logistic regression analyses indicated that hospitalization odds decreased 16.9% (P <.001) and 18.8% (P <.001) for every 10% increase in medication possession ratio and medication consistency, respectively. CONCLUSION: Small decreases in compliance with antipsychotics are associated with increased hospitalization risk among patients with schizophrenia in a managed care population.
OBJECTIVE: To investigate the relationship between partial compliance with antipsychotic medication and mental health hospitalization in managed care patients with schizophrenia. STUDY DESIGN: We performed a retrospective evaluation of 1499 outpatients with ≥1 antipsychotic claims and a diagnosis of schizophrenia in a managed care database (PHARMetrics). METHODS:Patients were followed for 12 months after their initial oral antipsychotic prescribing event. Compliance was estimated by gaps in medication therapy, medication consistency and persistence, and medication possession ratio. Categorical and logistic regression analyses modeled effects of compliance, age, and gender on hospitalization risk. RESULTS: The managed care cohort had an overall hospitalization risk of 5.9% during follow-up. Increased hospitalization risk was associated with lower partial compliance, as measured by 3 of the 4 definitions. Patients with a maximum gap of >30 days were 4.7 times more likely to be hospitalized than those with a maximum gap of 0 to 10 days (P <.001). Low medication consistency of <70% and a medication possession ratio of <70% were significantly associated with increased risk of hospitalization (P <.001). Logistic regression analyses indicated that hospitalization odds decreased 16.9% (P <.001) and 18.8% (P <.001) for every 10% increase in medication possession ratio and medication consistency, respectively. CONCLUSION: Small decreases in compliance with antipsychotics are associated with increased hospitalization risk among patients with schizophrenia in a managed care population.
Authors: Todd P Gilmer; Christian R Dolder; Jonathan P Lacro; David P Folsom; Laurie Lindamer; Piedad Garcia; Dilip V Jeste Journal: Am J Psychiatry Date: 2004-04 Impact factor: 18.112
Authors: Eric Q Wu; Howard G Birnbaum; Lizheng Shi; Daniel E Ball; Ronald C Kessler; Matthew Moulis; Jyoti Aggarwal Journal: J Clin Psychiatry Date: 2005-09 Impact factor: 4.384
Authors: Dana P Goldman; Geoffrey F Joyce; Jose J Escarce; Jennifer E Pace; Matthew D Solomon; Marianne Laouri; Pamela B Landsman; Steven M Teutsch Journal: JAMA Date: 2004-05-19 Impact factor: 56.272
Authors: Marcia Valenstein; Laurel A Copeland; Frederic C Blow; John F McCarthy; John E Zeber; Leah Gillon; C Raymond Bingham; Thomas Stavenger Journal: Med Care Date: 2002-08 Impact factor: 2.983
Authors: T Scott Stroup; Natalie A Bareis; Robert A Rosenheck; Marvin S Swartz; Joseph P McEvoy Journal: J Clin Psychiatry Date: 2018-11-27 Impact factor: 4.384
Authors: Marie-Hélène Lafeuille; Christian Frois; Michel Cloutier; Mei Sheng Duh; Patrick Lefebvre; Jacqueline Pesa; Zoe Clancy; John Fastenau; Mike Durkin Journal: Am Health Drug Benefits Date: 2016-10